Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Neogenomics Inc (NASDAQ:NEO)

9.22
Delayed Data
As of Dec 05
 +0.16 / +1.77%
Today’s Change
5.49
Today|||52-Week Range
9.60
+17.15%
Year-to-Date
SECTOR
Health Services
INDUSTRY
Medical/Nursing Services
MARKET CAP
$711.3M

Company Description

NeoGenomics, Inc. operates a network of cancer focused testing laboratories to provide genetic and molecular testing services. The company offers various testing services, including Cytogenetics, Fluorescence In-Situ Hybridization, Flow Cytometry, Immunohistochemistry, Hematopathology, Hereditary Cancer, Molecular Oncology and Pathology. The company operates through one segment: Laboratory Testing Segment. The Laboratory Testing segment delivers testing services to hospitals, pathologists, oncologists, other clinicians and researchers. The company was founded by Michael T. Dent on October 29, 1998 and is headquartered in Fort Myers, FL.

Contact Information

NeoGenomics, Inc.
12701 Commonwealth Drive
Fort Myers Florida 33913
P:(239) 768-0600
Investor Relations:
(239) 325-2001

Employees

Shareholders

Other institutional38.82%
Mutual fund holders19.75%
Individual stakeholders17.18%

Top Executives

Douglas M. Van OortExecutive Chairman & Chief Executive Officer
Mark MachulczVice President-Operations
Edwin Fred WeidigChief Accounting Officer & Finance Director
George A. CardozaChief Financial Officer
Maher AlbitarChief Medical Officer